Core Points - Nutriband Inc. will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on October 8, 2025, at 15:00 Eastern Standard Time, featuring a Q&A session [1] - The presentation will be available for viewing via a video webcast on Channelchek and will be archived for 90 days [3] - Nutriband is focused on developing transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch utilizing AVERSA™ technology [5] Company Overview - Nutriband's AVERSA™ technology incorporates aversive agents into transdermal patches to prevent drug abuse, ensuring safety while maintaining accessibility for patients in need [4] - The technology is protected by a broad intellectual property portfolio with patents granted in multiple countries, including the United States, Europe, and China [4] - The company is primarily engaged in the development of transdermal pharmaceutical products, aiming to address the issues of drug abuse and misuse [5] Event Details - Attendees can register for the virtual conference at no cost, and qualified investors can schedule one-on-one meetings with company management [2] - The event is organized by Noble Capital Markets, a full-service investment bank with a strong research team and a history of raising billions for companies [7] - Channelchek, launched by Noble, provides free access to institutional-quality research for emerging growth companies [8]

Core Points - Nutriband Inc. will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on October 8, 2025, at 15:00 Eastern Standard Time, featuring a Q&A session with the audience [1] - The presentation will be available for viewing via a video webcast on Channelchek and will be archived for 90 days [3] - Nutriband is focused on developing transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch utilizing AVERSA™ technology [5] Company Overview - Nutriband's AVERSA™ technology incorporates aversive agents into transdermal patches to prevent drug abuse, ensuring safety while maintaining accessibility for patients in need [4] - The company holds a broad intellectual property portfolio with patents granted in multiple countries, including the United States, Europe, and China [4] - Nutriband's primary engagement is in the development of transdermal products aimed at reducing the potential for drug misuse and accidental exposure [5] Event Details - Attendees can register for the virtual conference at no cost, and qualified investors can schedule one-on-one meetings with company management [2] - The event is organized by Noble Capital Markets, a full-service investment bank with a strong research team and a history of raising billions for companies [7] - Channelchek, launched by Noble in 2018, provides free access to institutional-quality research for emerging growth companies [8]

Company Overview - Nutriband Inc. is focused on developing transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch utilizing AVERSA™ technology [4] - The AVERSA™ technology aims to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, particularly fentanyl [3][4] Preferred Stock Dividend - Nutriband is issuing a 25% preferred stock dividend, where shareholders of record on July 25, 2025, will receive one preferred share for every four common shares held [1] - The pay date for the new issuance is set for August 5, 2025 [1] Conversion and Dividend Details - Each preferred share will be convertible into one share of common stock upon FDA approval of the AVERSA Fentanyl product [2] - If not converted, preferred shares will receive an annual cash dividend from the company's profits, as determined by the Board of Directors [2]

Company Overview - Nutriband Inc. has been added to multiple Russell indexes, including the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth Indexes as part of the 2025 reconstitution [1][2] - The company focuses on developing transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch utilizing AVERSA™ technology [6] Product and Technology - AVERSA™ technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, particularly fentanyl [5] - The potential peak annual US sales for AVERSA Fentanyl are estimated to be between $80 million and $200 million [2] Market Context - Russell indexes are widely utilized by investment managers and institutional investors, serving as benchmarks for approximately $10.6 trillion in assets as of June 2024 [3] - FTSE Russell, the global index provider, emphasizes the importance of adapting indexes to reflect the evolving US economy, with a transition to semi-annual reconstitution planned for 2026 [4]